文献速递胸部CT

基于CT的放射基因组学模型检测NSCLC中EGFR突变的外部验证及使用合成少数类过采样技术(SMOTE)建模时患病率的影响:经验教训

External Validation of a CT-Based Radiogenomics Model for the Detection of EGFR Mutation in NSCLC and the Impact of Prevalence in Model Building by Using Synthetic Minority Over Sampling (SMOTE): Lessons Learned.
PubMed 文献 · Acad Radiol · 2025-05-15

研究在独立NIH队列(n=140)中外部验证既往基于增强CT的EGFR突变放射基因组学模型,并用SMOTE模拟25%至50%的EGFR突变患病率构建六个数据集。外部验证显示原模型和已发表放射组学模型AUC均约0.5,而临床模型AUC为0.74;SMOTE提高敏感度但未改善总体AUC,患病率变化对AUC影响极小。

要点

  • 外部验证中放射基因组学模型诊断性能差,AUC约0.5。
  • 仅用临床变量的模型诊断准确度更高,AUC为0.74。
  • SMOTE过采样提高敏感度但未改善总体AUC。

核心结论

  • 外部验证未能重现既往放射基因组学模型的性能,而临床变量单独保留较强预测价值。
  • 基于SMOTE的过采样未提高诊断准确度,提示在EGFR预测中放射组学相对于临床数据的附加价值可能有限。
  • 未来放射基因组学模型的临床实施需要重视稳健的外部验证和数据共享。

研究设计与样本

  • 研究为外部验证研究,使用公开的基于美国国立卫生研究院(NIH)的NSCLC数据集(n=140)验证原始模型。
  • 为评估疾病患病率影响,创建六个SMOTE增强数据集,模拟EGFR突变患病率从25%至50%。
  • 共开发七个模型(一个来自原始数据,六个来自SMOTE增强数据),每个模型均经过严格交叉验证、特征选择和逻辑回归建模,并在NIH队列中测试。
  • 性能比较使用受试者工作特征曲线下面积(AUC),并对仅放射组学、仅临床和联合模型之间的差异进行统计学评估。

诊断标准与关键数值

  • 外部验证显示原模型和既往发表的EGFR放射组学模型的诊断性能均差,AUC约0.5。
  • 仅临床模型达到更高的诊断准确度,AUC为0.74。
  • SMOTE增强模型显示敏感度增加,但与仅临床模型相比总体AUC未改善。
  • 改变EGFR突变患病率对AUC影响极小。

临床应用与阅片要点

  • 原文结论指出,在EGFR预测中放射组学相对于临床数据的附加价值可能有限。
  • 原文强调未来放射基因组学模型的临床实施需要重视稳健的外部验证和数据共享。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Radiogenomics holds promise in identifying molecular alterations in nonsmall cell lung cancer (NSCLC) using imaging features. Previously, we developed a radiogenomics model to predict epidermal growth factor receptor (EGFR) mutations based on contrast-enhanced computed tomography (CECT) in NSCLC patients. The current study aimed to externally validate this model using a publicly available National Institutes of Health (NIH)-based NSCLC dataset and assess the effect of EGFR mutation prevalence on model performance through synthetic minority oversampling technique (SMOTE).

MATERIALS AND METHODS: The original radiogenomics model was validated on an independent NIH cohort (n=140). For assessing the influence of disease prevalence, six SMOTE-augmented datasets were created, simulating EGFR mutation prevalence from 25% to 50%. Seven models were developed (one from original data, six SMOTE-augmented), each undergoing rigorous cross-validation, feature selection, and logistic regression modeling. Models were tested against the NIH cohort. Performance was compared using area under the receiver operating characteristic curve (Area Under the Curve [AUC]), and differences between radiomic-only, clinical-only, and combined models were statistically assessed.

RESULTS: External validation revealed poor diagnostic performance for both our model and a previously published EGFR radiomics model (AUC ∼0.5). The clinical model alone achieved higher diagnostic accuracy (AUC 0.74). SMOTE-augmented models showed increased sensitivity but did not improve overall AUC compared to the clinical-only model. Changing EGFR mutation prevalence had minimal impact on AUC, challenging previous assumptions about the influence of sample imbalance on model performance.

CONCLUSION: External validation failed to reproduce prior radiogenomics model performance, while clinical variables alone retained strong predictive value. SMOTE-based oversampling did not improve diagnostic accuracy, suggesting that, in EGFR prediction, radiomics may offer limited value beyond clinical data. Emphasis on robust external validation and data-sharing is essential for future clinical implementation of radiogenomic models.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Kohan AA, Mirshahvalad SA, Hinzpeter R, et al. External Validation of a CT-Based Radiogenomics Model for the Detection of EGFR Mutation in NSCLC and the Impact of Prevalence in Model Building by Using Synthetic Minority Over Sampling (SMOTE): Lessons Learned. Acad Radiol. 2025. PMID: 40379588. doi:10.1016/j.acra.2025.04.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。